Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin’s lymphoma (NHL).

MEN1309 is a fully human monoclonal IgG1 antibody linked to a maytansinoid toxin called DM4 that targets the tumour antigen CD205.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multi-centre, open-label trial will enrol solid tumour patients in the first-dose escalation portion and NHL patients in the second dose escalation part.

The expansion cohorts will determine the recommended Phase II dose in specific indications of solid tumours and NHL.

Set to be conducted at oncology centres in Italy, Spain, Belgium and the UK, the trial will also assess the correlation between the clinical response and target antigen expression.

"Menarini has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline with OBT in clinical development."

Menarini Ricerche general manager Andrea Pellacani said: “MEN1309 could become an innovative treatment option for many cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Menarini has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline with OBT in clinical development.”

In patient derived models and xenografts, MEN1309 is reported to have demonstrated strong anti-tumour activity in triple-negative breast (TNBC), pancreatic and bladder cancers, and diffuse large B-cell lymphoma (DLBCL).

Menarini will supervise clinical development, proof-of-concept study, full development and regulatory approval of MEN1309 in Europe, Asia and Latin America, while OBT will manage full development, approval and commercialisation in North America and Japan.

The firms have previously collaborated to perform a Phase I dose escalation trial of MEN1112 in patients with relapsed / refractory acute myeloid leukaemia (AML).